Clinical trials: sponsored by University of Oxford
TB
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers
To assess the immunogenicity of M. bovis BCG (SSI strain), given intrademally in the standard dose used in clinical practice and to measure the development of the immune response in the first six months after administration. M.
- Trial name
- NCT00480714
- Testing
- BCG (SSI Strain)
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Psychosis
The Effectiveness of Supported Employment for People With Severe Mental Illness: an RCT in Six European Countries
The primary aim of the study was to determine the effectiveness of a form of supported employment, Individual Placement and Support (IPS) compared to existing good quality rehabilitation and vocational services for people with…
- Trial name
- EQOLISE (NCT00461318)
- Testing
- Individual placement and support (vocational rehabilitation)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
Atherosclerosis
Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients with established atherosclerosis.
- Trial name
- NCT00232531
- Testing
- Niaspan
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
This is a phase I study to test the immunogenicity of a recombinant vaccine based on Modified Vaccinia Ankara (MVA) expressing the antigen 85A (from Mycobacterium tuberculosis).
- Trial name
- NCT00427453
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.
- Trial name
- NCT00427830
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.
This study is to assesss the safety and immunogenicity of vaccine based on Modified Vaccinia Ankara (MVA) expressing the 85A antigen (from Mycobacterium. tuberculosis).
- Trial name
- NCT00423566
- Testing
- MVA85A (Tuberculosis vaccine)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers
A Phase I study of the Safety and immunogenicity of MVA85A in healthy Gambian volunteers
- Trial name
- NCT00423839
- Testing
- MVA85A (Tuberculosis vaccine)
- Where
- The Gambia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Malaria, Falciparum
Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen
The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.
- Trial name
- NCT00408668
- Testing
- PEV3A, FP9 ME-TRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Acute Myocardial Infarction
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible…
- Trial name
- NCT00222573
- Testing
- clopidogrel and metoprolol
- Where
- 2 sites in China, United Kingdom
- Volunteers
- 46,000 people
- Sponsor
- University of Oxford
Village Children
Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6
Randomisation of 72 large rural areas ("blocks") into a 2 x 2 trial of six- monthly treatment of all village children aged 1-5 with albendazole(400mg), vitamin A (200000 iu), both or neither.
- Trial name
- NCT00222547
- Testing
- Vitamin A, Albendazole
- Where
- India
- Volunteers
- 720,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hepatitis B, Liver Neoplasms
Qidong Hepatitis B Intervention Study
During 1983-1990 in the Jiangsu province of China, 80,000 infants were randomised by area of birth between control, standard Hepatitis B vaccination (at 0, 1 and 6 months of age) and standard vaccination plus a booster dose at…
- Conditions
- Hepatitis B, Liver Neoplasms, Liver Diseases
- Trial name
- NCT00222664
- Testing
- Hep-V Vax
- Where
- 3 sites in China, United Kingdom
- Volunteers
- 80,000 people
- Sponsor
- University of Oxford
Depression
An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression
The purpose of this study is to determine the effectiveness of a simple marketing intervention in changing attitudes towards depression and its treatment among university students.
- Trial name
- NCT00122083
- Testing
- Health education information
- Where
- United Kingdom
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- University of Oxford